IDH mutations in cancer and progress toward development of targeted therapeutics

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 599-608

  Dang, L ^a   Yen, K ^a   Attar, E C ^a  

^a AGIOS PHARMACEUTICALS   (United States)

Author keywords

Glioma; Hematologic malignancy; IDH1; IDH2; Isocitrate dehydrogenase; Small molecule inhibitor

Indexed keywords

AG 120; AG 221; AG 881; ANTINEOPLASTIC AGENT; AZACITIDINE; BORTEZOMIB; CYTARABINE; DECITABINE; ETOPOSIDE; IDARUBICIN; IDH 305; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; RETINOIC ACID; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; ENZYME INHIBITOR; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CHONDROSARCOMA; DISEASE FREE SURVIVAL; DNA METHYLATION; ENCHONDROMA; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HUMAN; IDH1 GENE; IDH2 GENE; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; MISSENSE MUTATION; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SOMATIC MUTATION; TREATMENT RESPONSE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

CARCINOGENESIS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84964691616     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw013     Document Type: Review

References (105)

1. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
2. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
3. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
4. Kosmider O, Gelsi-Boyer V, Slama L et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/ myeloproliferative neoplasms. Leukemia 2010; 24: 1094-1096.
5. Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broadbased tumor genotyping. Oncologist 2012; 17: 72-79.
6. Kranendijk M, Struys EA, Salomons GS et al. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis 2012; 35: 571-587.
7. Kranendijk M, Struys EA, van Schaftingen E et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 2010; 330: 336.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
9. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005; 4: 6-13.
10. Aykin-Burns N, Ahmad IM, Zhu Y et al. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 2009; 418: 29-37.
11. Kirkman HN, Rolfo M, Ferraris AM, Gaetani GF. Mechanisms of protection of catalase by NADPH. Kinetics and stoichiometry. J Biol Chem 1999; 274: 13908-13914.
12. Bleeker FE, Atai NA, Lamba S et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010; 119: 487-494.
13. Metallo CM, Gameiro PA, Bell EL et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012; 481: 380-384.
14. Wise DR, Ward PS, Shay JE et al. Hypoxia promotes isocitrate dehydrogenasedependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 2011; 108: 19611-19616.
15. Mullen AR, Wheaton WW, Jin ES et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481: 385-388.
16. Reitman ZJ, Duncan CG, Poteet E et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem 2014; 289: 23318-23328.
17. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 2011; 17: 641-649.
18. Losman JA, Kaelin WG, Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836-852.
19. Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
20. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
21. Gross S, Cairns RA, Minden MD et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
22. Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
23. Chowdhury R, Yeoh KK, Tian YM et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463-469.
24. Koivunen P, Lee S, Duncan CG et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-488.
25. Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
26. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
27. Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478.
28. Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
29. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
30. Kernytsky A, Wang F, Hansen E et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 2015; 125: 296-303.
31. Rohle D, Popovici-Muller J, Palaskas N et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630.
32. Wang F, Travins J, DeLaBarre B et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622-626.
33. Sasaki M, Knobbe CB, Munger JC et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-659.
34. Chen C, Liu Y, Lu C et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013; 27: 1974-1985.
35. Kats LM, Reschke M, Taulli R et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014; 14: 329-341.
36. Welch JS, Ley TJ, Link DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
37. Fathi AT, Sadrzadeh H, Borger DR et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012; 120: 4649-4652.
38. Pardanani A, Lasho TL, Finke CM et al. IDH1 and IDH2 mutation analysis in chronicand blast-phase myeloproliferative neoplasms. Leukemia 2010; 24: 1146-1151.
39. Thol F, Weissinger EM, Krauter J et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668-1674.
40. Patnaik MM, Hanson CA, Hodnefield JM et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012; 26: 101-105.
41. Tefferi A, Jimma T, Sulai NH et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26: 475-480.
42. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19: 764-772.
43. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
44. Lai A, Kharbanda S, Pope WB et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011; 29: 4482-4490.
45. Lass U, Numann A, von Eckardstein K et al. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. PLoS One 2012; 7: e41298.
46. Juratli TA, Kirsch M, Robel K et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 2012; 108: 403-410.
47. Saha SK, Parachoniak CA, Ghanta KS et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature 2014; 513: 110-114.
48. Borger DR, Goyal L, Yau T et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res 2014; 20: 1884-1890.
49. Lu C, Venneti S, Akalin A et al. Induction of sarcomas by mutant IDH2. Genes Dev 2013; 27: 1986-1998.
50. Amary MF, Bacsi K, Maggiani F et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224: 334-343.
51. Amary MF, Ye H, Forbes G et al. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. Virchows Arch 2015; 466: 217-222.
52. Hirata M, Sasaki M, Cairns RA et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. Proc Natl Acad Sci USA 2015; 112: 2829-2834.
53. Pansuriya TC, van Eijk R, d'Adamo P et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 1256-1261.
54. DiNardo CD, Jabbour E, Ravandi F et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 2015; Epub ahead of print.
55. Im AP, Sehgal AR, Carroll MP et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014; 28: 1774-1783.
56. DiNardo CD, Ravandi F, Agresta S et al. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 2015; 90: 732-736.
57. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-6007.
58. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
59. Eckel-Passow JE, Lachance DH, Molinaro AM et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372: 2499-2508.
60. Brat DJ, Verhaak RG, Aldape KD et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372: 2481-2498.
61. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154.
62. Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-718.
63. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880.
64. Cairncross JG, Wang M, Jenkins RB et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32: 783-790.
65. van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16: 1597-1604.
66. Amary MF, Damato S, Halai D et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43: 1262-1265.
67. Walden MJ, Murphey MD, Vidal JA. Incidental enchondromas of the knee. AJR Am J Roentgenol 2008; 190: 1611-1615.
68. Hong ED, Carrino JA, Weber KL, Fayad LM. Prevalence of shoulder enchondromas on routine MR imaging. Clin Imaging 2011; 35: 378-384.
69. Hopyan S, Gokgoz N, Poon R et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 2002; 30: 306-310.
70. Kato Kaneko M, Liu X, Oki H et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. Cancer Sci 2014; 105: 744-748.
71. Fathi AT, Sadrzadeh H, Comander AH et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist 2014; 19: 602-607.
72. Paschka P, Schlenk RF, Gaidzik VI et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643.
73. Marcucci G, Maharry K, Wu YZ et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348-2355.
74. Boissel N, Nibourel O, Renneville A et al. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2011; 117: 3696-3697.
75. Green CL, Evans CM, Zhao L et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118: 409-412.
76. SongTao Q, Lei Y, Si G et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012; 103: 269-273.
77. Houillier C, Wang X, Kaloshi G et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-1566.
78. van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350.
79. Buckner J, Shaw E, Pugh S et al. IDH1 R132H mutations in NRG oncology/RTOG 9802: phase III study of radiation therapy (RT) alone vs RT plus procarbazine, CCNU, and vincristine (PCV) in patients with low grade glioma (LGG). Neuro Oncol 2015; 17(suppl 5): ATCT-09.
80. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 2015; 5: e304.
81. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515.
82. DiNardo CD, Patel KP, Garcia-Manero G et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma 2014; 55: 1925-1929.
83. Metzeler KH, Walker A, Geyer S et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012; 26: 1106-1107.
84. Emadi A, Faramand R, Carter-Cooper B et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol 2015; 90: E77-E79.
85. Cruz FD, Matushansky I. Solid tumor differentiation therapy-is it possible? Oncotarget 2012; 3: 559-567.
86. Turcan S, Fabius AW, Borodovsky A et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 2013; 4: 1729-1736.
87. Borodovsky A, Salmasi V, Turcan S et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013; 4: 1737-1747.
88. Xu WP, Zhang X, Xie WF. Differentiation therapy for solid tumors. J Dig Dis 2014; 15: 159-165.
89. DiNardo C, Stein EM, Altman JK et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase I study of IDH2 mutation-positive advanced hematologic malignancies. In European Hematology Association Learning Center 13 June 2015; 100710: Abstract P569.
90. de Botton S, Pollyea DA, Stein EM et al. Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced, IDH1-mutant hematological malignancies. In European Hematology Association Learning Center Jun 13, 2015; 100704: Abstract P563.
91. Schumacher T, Bunse L, Pusch S et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512: 324-327.
92. Pellegatta S, Valletta L, Corbetta C et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun 2015; 3: 4.
93. Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
94. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
95. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
96. Gore SD, Fenaux P, Santini V et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-1072.
97. Dombret H, Seymour JF, Butrym A et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126: 291-299.
98. Kantarjian HM, Thomas XG, Dmoszynska A et al. Multicenter, randomized, openlabel, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
99. Cheson BD, Byrd JC, Rai KR et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30: 2820-2822.
100. Choi H, Charnsangavej C, de Castro Faria S et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619-1628.
101. Estey E, Levine RL, Lowenberg B. Current challenges in clinical development of 'targeted therapies': the case of acute myeloid leukemia. Blood 2015; 125: 2461-2466.
102. Lo-Coco F, Avvisati G, Vignetti M et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369: 111-121.
103. DiNardo CD, Propert KJ, Loren AW et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013; 121: 4917-4924.
104. Janin M, Mylonas E, Saada V et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2014; 32: 297-305.
105. Choi C, Ganji S, An Z et al. Prospective longitudinal in vivo 1H MRS study of 2-hydroxyglutarate in patients with IDH mutated gliomas. In World Molecular Imaging Congress, Seoul, Korea, 2014; 17-20 September 2014.